ArticleNeural regeneration research2026
Advances in metabolomics of biomarkers for ischemic stroke: From bench to clinic.
Article in Neural regeneration research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Stroke-induced gut microbiome dysbiosis accelerates Alzheimer's disease progression.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic stroke, a neurological impairment caused by cerebral vascular occlusion, accounts for 87% of the cases of stroke. Recent studies have shown that changes in the abundance of metabolites can directly reveal the cellular phenotypes and identify the clinical implications of stroke diagnosis and therapy. However, systematic research to clarify the relationship between biomarkers and the mechanisms of ischemic stroke remains limited. In this study, we reviewed articles on ischemic stroke metabolites from 2005 to 2024, identified metabolites showing significant changes, and constructed a metabolite database based on the findings from 128 studies. The database included 125 differential metabolites detected in a middle cerebral artery occlusion mouse model, 246 detected in an middle cerebral artery occlusion rat model, and 764 identified in ischemic stroke patient samples. Differential metabolites from various samples were then screened and classified into positive and negative categories based on their correlation with stroke prognoses. Based on this analysis, three positive metabolites and two negative metabolites were identified. Glutamic acid, glycerol, and 1-octadecanoyl-sn-glycero-3-phosphocholine (LysoPC(18:0)) were further recognized as potential biomarkers. Imbalances in metabolic pathways such as alanine, aspartate, and glutamate metabolism as well as the citrate cycle (tricarboxylic acid cycle) were analyzed. These imbalances may influence the pathogenesis of ischemic stroke by altering biological processes such as excitotoxicity, oxidative stress, inflammation, and energy metabolism. The identification and analysis of these potential biomarkers may provide valuable targets and strategies for prediction, diagnosis, and prognostic assessment of ischemic stroke.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.